By Daniella Parra
Vaxxinity, Inc. (Nasdaq: VAXX) said it demonstrated that VXX-401 lowers LDL cholesterol, supporting its potential for treating hypercholesterolemia.
The VXX-401, a synthetic peptide vaccine, aims to provide a safe and effective solution against heart disease by targeting PCSK9, the company said in a statement.
The studies were published in the Journal of Lipid Research, which show that VXX-401 induces a strong antibody response against PCSK9, resulting in a 44% LDL cholesterol reduction in cynomolgus monkeys, it said.
“Vaxxinity is committed to providing scalable, accessible, game-changing solution for worldwide heart health,” said Mei Mei Hu, CEO of Vaxxinity. “Despite multiple approved medications for LDL-C reduction, heart disease remains the number one killer in the world. A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.”
Editor@Executives-edge.com
